<SEC-DOCUMENT>0001654954-18-006703.txt : 20180615
<SEC-HEADER>0001654954-18-006703.hdr.sgml : 20180615
<ACCEPTANCE-DATETIME>20180615163024
ACCESSION NUMBER:		0001654954-18-006703
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180615
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180615
DATE AS OF CHANGE:		20180615

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TG THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001001316
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				363898269
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32639
		FILM NUMBER:		18902572

	BUSINESS ADDRESS:	
		STREET 1:		2 GANSEVOORT STREET, 9TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10014
		BUSINESS PHONE:		(212) 554-4484

	MAIL ADDRESS:	
		STREET 1:		2 GANSEVOORT STREET, 9TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10014

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MANHATTAN PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20030310

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ATLANTIC TECHNOLOGY VENTURES INC
		DATE OF NAME CHANGE:	20000330

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ATLANTIC PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v061518_8k.htm
<DESCRIPTION>8-K
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2018 Issuer Direct Corporation -->
<title>&#xA0;</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">UNITED STATES</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">SECURITIES AND EXCHANGE
COMMISSION</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">WASHINGTON, D.C.</font> <font style="font-weight: bold"><font style="font-size: 13px">20549</font></font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">_____________</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">FORM 8-K</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">_____________</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">CURRENT REPORT</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">Pursuant to Section 13 or 15(d) of
the</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">Securities Exchange Act of
1934</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 19px; text-indent: 0px"></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Date of report
(Date of earliest event reported): <font style="font-weight: bold">June 15, 2018</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"></div>
<div style="text-align: left; margin-left: 0px; margin-right: 19px; text-indent: 0px"></div>
<div style="text-align: left; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">TG Therapeutics, Inc.</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(Exact Name of
Registrant as Specified in Charter)</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 19px; text-indent: 0px"></div>
<div style="text-align: left; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; font-family: inherit; font-size: inherit;text-align: left; width: 100%;">
<tr style="vertical-align: top">
<td style="width: 32%">
<div style="text-align: center; margin-left: 12px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">Delaware</font></font></div>
<div style="text-align: center; margin-left: 12px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(State or Other
Jurisdiction</font></div>
<div style="text-align: center; margin-left: 12px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">of
Incorporation)</font></div>
</td>
<td style="width: 29%">
<div style="text-align: center; margin-left: 12px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">001-32639</font></font></div>
<div style="text-align: center; margin-left: 12px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(Commission File
Number)</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 39%">
<div style="text-align: center; margin-left: 12px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">36-3898269</font></font></div>
<div style="text-align: center; margin-left: 12px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(IRS Employer
Identification No.)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 19px; text-indent: 0px"></div>
<div style="text-align: left; margin-left: 0px; margin-right: 19px; text-indent: 0px"></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">2 Gansevoort Street, 9<font style="vertical-align: super; font-size: 70%">th</font>
Floor</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">New York, New York 10014</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(Address of
Principal Executive Offices)</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">(212) 554-4484</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(Registrant's
telephone number, including area code)</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 14px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">
<font style="font-size: 13px">&#xA0; &#xA0;&#xA0;&#xA0;&#xA0;
&#x2610;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Written
communications pursuant to Rule 425 under the Securities
Act.</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">
<font style="font-size: 13px">&#xA0; &#xA0;&#xA0;&#xA0;&#xA0;
&#x2610;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Soliciting material
pursuant to Rule 14a-12 under the Exchange Act.</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">
<font style="font-size: 13px">&#xA0; &#xA0;&#xA0;&#xA0;&#xA0;
&#x2610;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange
Act.</font></div>
</div>
</div>
<div style="text-align: left; display: table; margin-left: 24px">
<div style="text-align: left; display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">
<font style="font-size: 13px">&#xA0; &#xA0; &#xA0;&#xA0;
&#x2610;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act.</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">&#xA0;</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR
&#xA7;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR &#xA7;240.12b-2). Emerging growth company
&#x2610;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.</font> <font style="font-size: 13px; font-family: Times New Roman">&#x2610;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 19px; text-indent: 0px"></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">Item 8.01. Other Events.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">&#xA0;</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0;
&#xA0;&#xA0;&#xA0; On June 15, 2018, TG Therapeutics, Inc. (the
&#x201C;Company&#x201D;) issued a press release announcing the
presentation of an integrated analysis of long term safety data of
umbralisib (TGR-1202), the Company&#x2019;s PI3K delta inhibitor, as
well as the first preclinical data presentation of TG-1701, the
Company&#x2019;s orally available and covalently-bound BTK
inhibitor, at the 23rd Congress of European Hematology Association
(EHA). On June 15, 2018, the Company also announced updated
clinical data from its ongoing Phase I study evaluating umbralisib
(TGR-1202), the Company's PI3K delta inhibitor in combination with
ruxolitinib, the JAK 1/2 inhibitor, in ruxolitinib experienced
patients with myelofibrosis (MF), at the 23rd Congress of EHA.
Copies of the press releases are being filed as Exhibits 99.1 and
Exhibits 99.2 and incorporated in this Item by
reference</font><font style="font-family: Times New Roman">.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">Item 9.01 Financial Statements And
Exhibits.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(d)
Exhibits.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: -48px"><font style="font-size: 13px; font-family: Times New Roman"><a href="v061518_ex991.htm">99.1</a>&#xA0; Press Release, dated June 15,
2018.</font></div>
<div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: -48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: -48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: -48px"><font style="font-size: 13px; font-family: Times New Roman"><a href="v061518_ex992.htm">99.2</a>&#xA0; Press Release, dated June 15,
2018.</font></div>
<div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: -48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
<div id="pb" style="margin-left: 0px; margin-right: 0px; text-align: center; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000"><!--page break line--></div>
<div id="hdr" style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: -48px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 48px; margin-right: 0px; text-indent: -48px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">SIGNATURES</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 19px; text-indent: 0px"></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 19px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; font-family: inherit; font-size: inherit;text-align: left; width: 100%;">
<tr style="vertical-align: top">
<td style="width: 50%; text-indent: 0; padding-bottom: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="width: 50%; text-indent: 0; padding-bottom: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">TG Therapeutics, Inc.</font></font></div>
</td>
</tr><tr style="vertical-align: top">
<td style="text-indent: 0; padding-bottom: 0px">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="text-indent: 0; padding-bottom: 0px">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(Registrant)</font></div>
</td>
</tr><tr style="vertical-align: top">
<td style="text-indent: 0; padding-bottom: 0px">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="text-indent: 0; padding-bottom: 0px">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
</tr><tr style="vertical-align: top">
<td style="text-indent: 0; padding-bottom: 0px">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="text-indent: 0; padding-bottom: 0px">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
</tr><tr style="vertical-align: top">
<td style="text-indent: 0; padding-bottom: 0px">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="text-indent: 0; padding-bottom: 0px">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
</tr><tr style="vertical-align: top">
<td style="text-indent: 0; padding-bottom: 0px">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Date: June 15,
2018</font></div>
</td>
<td style="text-indent: 0; padding-bottom: 0px">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
</tr><tr style="vertical-align: top">
<td style="text-indent: 0; padding-bottom: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="text-indent: 0; padding-bottom: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:&#xA0;<font style="text-decoration: underline">/s/
Sean A.
Power&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></font></div>
</td>
</tr><tr style="vertical-align: top">
<td style="text-indent: 0; padding-bottom: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="text-indent: 0; padding-bottom: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Sean A.
Power</font></div>
</td>
</tr><tr style="vertical-align: top">
<td style="text-indent: 0; padding-bottom: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="text-indent: 0; padding-bottom: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Chief Financial
Officer</font></div>
</td>
</tr><tr style="vertical-align: top">
<td style="text-indent: 0; padding-bottom: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="text-indent: 0; padding-bottom: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v061518_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2018 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr" style="text-align: right"><font style="font-weight: bold">Exhibit
99.1</font></div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
TG Therapeutics, Inc. Announces Clinical and Preclinical Data
Presentations at the 23<font style="font-size: 70%; vertical-align: top">rd</font> Congress of the
European Hematology Association</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">NEW
YORK, NY (June 15, 2018) - TG Therapeutics, Inc. (NASDAQ: TGTX),
today announced the presentation of an integrated analysis of long
term safety data of umbralisib (TGR-1202), the Company&#x2019;s PI3K
delta inhibitor, either dosed as a single agent and in combination,
in patients with relapsed or refractory lymphoid malignancies, as
well as the first preclinical data presentation of TG-1701, the
Company&#x2019;s orally available and covalently-bound BTK
inhibitor. Data from these trials are being presented today during
the 23<font style="font-size: 70%; vertical-align: top">rd</font>
Congress of the European Hematology Association (EHA).</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Michael
S. Weiss, the Company's Executive Chairman and Chief Executive
Officer, stated, &#x201C;We are extremely pleased to present updated
data from our integrated safety analyses of umbralisib. There is a
generally held belief that severe toxicities are more common
following 6 months of exposure on a PI3K delta inhibitor. While
this has held true for first generation delta inhibitors, we are
pleased to present data from 177 patients on daily umbralisib for
more than 6 months, ranging upwards of 5+ years, and believe the
long-term follow-up data demonstrates that umbralisib has a
differentiated safety profile, uniquely distinct from prior
generation PI3K delta inhibitors.&#x201D; Mr. Weiss continued,
&#x201C;The differentiated safety profile of umbralisib is critical
as we think about potential triple and quad combination strategies,
especially in combination with our novel, proprietary BTK
inhibitor, TG-1701, for which we also presented some exciting
pre-clinical data. The kinase profile of TG-1701 looks quite
competitive with the most specific BTK inhibitors and more
selective than ibrutinib. We look forward to seeing more data on
TG-1701 and expect to open a TG sponsored Phase 1/2 trial later
this year.&#x201D;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Highlights
from today&#x2019;s presentations include the
following:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
<font style="text-decoration: underline">Poster
Presentation:</font> Long term integrated safety analysis of
umbralisib (TGR-1202), a PI3K delta/CK1-epsilon inhibitor with a
differentiated safety profile in patients with relapsed/refractory
lymphoid malignancies</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
This presentation builds on a prior integrated analysis of 347
patients with relapsed or refractory lymphoid malignancies
presented last year. The presentation includes data that were
pooled from 4 completed or ongoing Phase 1 or 2 studies containing
umbralisib, focusing on 177 patients who have been on daily
umbralisib for a minimum of 6 months. Patients were heavily
pretreated, with 45% of patients having seen 3 or more prior lines
of therapy.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Highlights from this poster include:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Umbralisib
continues to exhibit a differentiated safety profile compared to
prior generation PI3K delta inhibitors</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">177
patients have been treated with daily umbralisib for 6+ months,
with a median duration of exposure of 1.3 years, and 33% patients
on drug 2+ years and the longest patients on daily umbralisib for
over 5 years</font></div>
</div>
</div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Serious
adverse events occurring in &gt;1% of patients were limited to
pneumonia (3%), diarrhea (2%), and cellulitis (2%)</font></div>
</div>
</div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Only
2% of patients discontinued as a result of diarrhea/colitis after
being on umbralisib for more than 6 months</font></div>
</div>
</div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Discontinuations
due to other adverse events (AEs) of interest for prior generation
PI3K inhibitors were also rare</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; font-style: italic; text-decoration: underline">
Poster Presentation:</font><font style="color: #000000">&#xA0;</font><font style="font-weight: bold; font-style: italic">TG-1701 is a novel, orally
available, and covalently-bound BTK inhibitor</font></font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">TG-1701, a novel,
specific and covalent BTK inhibitor, is more selective than
ibrutinib toward a set of kinases</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">BTK occupancy
assays in vitro and in vivo suggest that 100% occupancy can be
reached using low doses of TG-1701 in human dose escalation
clinical trial</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">In pre-clinical
experiments, TG-1701 inhibited the phosphorylation of BTK and other
kinases downstream of the BCR pathway.</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">In cellular and
animal models of b-cell malignancies, TG-1701 demonstrated similar
antitumor efficacy to ibrutinib and acalabrutinib</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
PRESENTATION DETAILS</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
above referenced presentations are now available on the
Publications page, located within the Pipeline section, of the
Company&#x2019;s website at <font style="text-decoration: underline; color: #0000FF">www.tgtherapeutics.com/publications.cfm</font>.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
ABOUT TG THERAPEUTICS, INC.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><a name="_Hlk502743796"><!--anchor--></a>TG Therapeutics&#xA0;is a
biopharmaceutical company focused on the acquisition, development
and commercialization of novel treatments for B-cell malignancies
and autoimmune diseases. Currently, the company is developing two
therapies targeting hematological malignancies and autoimmune
diseases. Ublituximab (TG-1101) is a novel, glycoengineered
monoclonal antibody that targets a specific and unique epitope on
the CD20 antigen found on mature B-lymphocytes.&#xA0;TG
Therapeutics&#xA0;is also developing umbralisib (TGR-1202), an
orally available PI3K delta inhibitor. The delta isoform of PI3K is
strongly expressed in cells of hematopoietic origin and is believed
to be important in the proliferation and survival of
B&#x2010;lymphocytes. Both ublituximab and umbralisib, or the
combination of which is referred to as "U2", are in Phase 3
clinical development for patients with hematologic malignancies,
with ublituximab also in Phase 3 clinical development for Multiple
Sclerosis. Additionally, the Company has recently brought its
anti-PD-L1 monoclonal antibody into Phase 1 development and aims to
bring additional pipeline assets into the clinic in the
future.&#xA0; TG Therapeutics&#xA0;is headquartered in&#xA0;New
York City.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Cautionary Statement</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Some of the statements included in this press release or in the
abstracts mentioned in this press release may be forward-looking
statements that involve a number of risks and uncertainties.
&#xA0;For those statements, we claim the protection of the safe
harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. Among the factors that
could cause our actual results to differ materially are the
following: our ability to successfully and cost-effectively
complete preclinical and clinical trials;</font> the risk that
early clinical trial results (both safety and efficacy), that may
have supported the acceptance of our data for presentation or
influenced our decision to proceed with additional clinical trials,
will not be reproduced in future studies or in the final
presentations<font style="color: #000000">;</font> the risk that
the differentiated tolerability profile for umbralisib observed
will not be reproduced in full presentations or later larger
studies; the risk that umbralisib is not a differentiated PI3K
delta inhibitor; the risk that the combination of ublituximab
(TG-1101) and umbralisib (TGR-1202), referred to as U2, and being
studied in the UNITY clinical trials and other studies, will not
prove to be safe and efficacious for any indication or will not
prove to be a safe and efficacious backbone for future triple or
quad therapies; the risk that we will not open a TG sponsored Phase
1/2 trial of TG-1701; the risk that we will not study the triple
combination of ublituximab, umbralisib and TG-1701 <font style="color: #000000">and other risk factors identified from time to
time in our reports filed with the&#xA0;Securities and Exchange
Commission. &#xA0;Any forward-looking statements set forth in this
press release speak only as of the date of this press release. We
do not undertake to update any of these forward-looking statements
to reflect events or circumstances that occur after the date
hereof. This press release and prior releases are available
at&#xA0;</font><font style="text-decoration: underline; color: #000000">www.tgtherapeutics.com</font><font style="color: #000000">.
The information found on our website is not incorporated by
reference into this press release and is included for reference
purposes only.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
CONTACT:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Jenna
Bosco</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">SVP,
Corporate Communications</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">TG
Therapeutics, Inc.</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Telephone:
212.554.4351</font></div>
</div>
</div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Email:
ir@tgtxinc.com</font></div>
</div>
</div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
</div>
</div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
</div>
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>v061518_ex992.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2018 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 12px"><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-weight: bold">Exhibit 99.2</font></font><br></font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
TG Therapeutics, Inc. Announces Oral Presentation of Umbralisib
plus Ruxolitinib in Patients with Myelofibrosis at the
23<font style="font-size: 70%; vertical-align: top">rd</font>
Congress of the European Hematology Association</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Data demonstrates that the addition of umbralisib to ruxolitinib
can induce responses in patients with sub-optimal response to
ruxolitinib single agent</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">NEW
YORK, NY (June 15, 2018) - TG Therapeutics, Inc. (NASDAQ: TGTX),
today announced updated clinical data from its ongoing Phase I
study evaluating umbralisib (TGR-1202), the Company&#x2019;s PI3K
delta inhibitor in combination with ruxolitinib, the JAK 1/2
inhibitor, in ruxolitinib experienced patients with myelofibrosis
(MF). Data from this trial are being presented this morning during
the 23<font style="font-size: 70%; vertical-align: top">rd</font>
Congress of the European Hematology Association (EHA).</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Michael
S. Weiss, the Company's Executive Chairman and Chief Executive
Officer, stated, &#x201C;The data presented in patients with
myelofibrosis represents yet another unique opportunity for
umbralisib, in this case providing a treatment option to patients
who are not achieving an optimal response to ruxolitinib
monotherapy. This type of study highlights the unique breadth of
activity of PI3K delta inhibition across hematological malignancies
and underscores the importance of umbralisib&#x2019;s safety
profile, that permits a wide range of combinations.&#x201D; Mr.
Weiss continued, &#x201C;We look forward to evaluating this
combination further, potentially in a randomized pivotal
setting.&#x201D;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Highlights
from this morning&#x2019;s presentation include the
following:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
<font style="text-decoration: underline">Oral Presentation:</font>
Resurrecting response to ruxolitinib: a phase I study testing the
combination of ruxolitinib and the PI3Kdelta inhibitor umbralisib
in ruxolitinib-experienced myelofibrosis (Abstract Number
S133)</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">This
oral presentation includes data from patients with myelofibrosis
treated with the combination of ruxolitinib, the JAK1/2 inhibitor
and umbralisib (TGR-1202). Importantly, per protocol, all enrolled
patients were on a stable dose of ruxolitinib monotherapy and had
achieved their best response to ruxolitinib prior to enrolling to
receive umbralisib. Presentation highlights included:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The combination of
umbralisib + ruxolitinib was well-tolerated with limited Grade 3/4
adverse events;</font></div>
</div>
</div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Dose-limiting
toxicities of asymptomatic amylase/lipase elevations were observed
of unclear clinical consequence;</font></div>
</div>
</div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px"><a name="_Hlk516812181"><!--anchor--></a>Only one event
of colitis (in a patient with underlying GI disorder at study
entry) and no pneumonitis was observed.</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Increases in
hemoglobin, improvements in spleen size, and reduction in symptoms
meeting IWG-MRT criteria for clinical improvement were seen in 13
(57%) ruxolitinib-experienced myelofibrosis patients;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Importantly, 2
patients (9%) achieved a durable complete remission after
progressing on ruxolitinib;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The addition of
umbralisib to ruxolitinib demonstrates the ability to augment or
resurrect a response in myelofibrosis patients who had suboptimal
or lost response to ruxolitinib alone.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
PRESENTATION DETAILS</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
above referenced presentation is now available on the Publications
page, located within the Pipeline section, of the Company&#x2019;s
website at <font style="text-decoration: underline; color: #0000FF">www.tgtherapeutics.com/publications.cfm</font>.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
ABOUT TG THERAPEUTICS, INC.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">TG
Therapeutics&#xA0;is a biopharmaceutical company focused on the
acquisition, development and commercialization of novel treatments
for B-cell malignancies and autoimmune diseases. Currently, the
company is developing two therapies targeting hematological
malignancies and autoimmune diseases. Ublituximab (TG-1101) is a
novel, glycoengineered monoclonal antibody that targets a specific
and unique epitope on the CD20 antigen found on mature
B-lymphocytes.&#xA0;TG Therapeutics&#xA0;is also developing
umbralisib (TGR-1202), an orally available PI3K delta inhibitor.
The delta isoform of PI3K is strongly expressed in cells of
hematopoietic origin and is believed to be important in the
proliferation and survival of B&#x2010;lymphocytes. Both ublituximab
and umbralisib, or the combination of which is referred to as "U2",
are in Phase 3 clinical development for patients with hematologic
malignancies, with ublituximab also in Phase 3 clinical development
for Multiple Sclerosis. Additionally, the Company has recently
brought its anti-PD-L1 monoclonal antibody into Phase 1 development
and aims to bring additional pipeline assets into the clinic in the
future.&#xA0; TG Therapeutics&#xA0;is headquartered in&#xA0;New
York City.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Cautionary Statement</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Some of the statements included in this press release or in the
abstracts mentioned in this press release may be forward-looking
statements that involve a number of risks and uncertainties.
&#xA0;For those statements, we claim the protection of the safe
harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. Among the factors that
could cause our actual results to differ materially are the
following: our ability to successfully and cost-effectively
complete preclinical and clinical trials;</font> the risk that
early clinical trial results (both safety and efficacy), that may
have supported the acceptance of our data for presentation or
influenced our decision to proceed with additional clinical trials,
will not be reproduced in future studies or in the final
presentations; the risk that the differentiated tolerability
profile for umbralisib observed will not be reproduced in full
presentations or later larger studies the risk that we will not
evaluate the combination of ruxolitinib and umbralisib in
myelofibrosis or any other indication; <font style="color: #000000">and other risk factors identified from time to
time in our reports filed with the&#xA0;Securities and Exchange
Commission. &#xA0;Any forward-looking statements set forth in this
press release speak only as of the date of this press release. We
do not undertake to update any of these forward-looking statements
to reflect events or circumstances that occur after the date
hereof. This press release and prior releases are available
at&#xA0;</font><font style="text-decoration: underline; color: #000000">www.tgtherapeutics.com</font><font style="color: #000000">.
The information found on our website is not incorporated by
reference into this press release and is included for reference
purposes only.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
CONTACT:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Jenna
Bosco</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">SVP,
Corporate Communications</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">TG
Therapeutics, Inc.</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Telephone:
212.554.4351</font></div>
</div>
</div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Email:
ir@tgtxinc.com</font></div>
<div style="text-align: left; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px"><br>
</font></div>
<div style="text-align: left; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px"><br>
</font></div>
</div>
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
